Vincent Huberty

Vincent Huberty

Auto-generated profile, based on publicly available information

Vincent Huberty

Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
VHVincent Huberty
Vincent Huberty
SBSouraya El Bacha
Souraya El Bacha
DBDaniel Blero
Daniel Blero
OMOlivier Le Moine
Olivier Le Moine
SHSergio Hassid
Sergio Hassid
JDJacques Devière
Jacques Devière

28 October 2020 in Gut
Verified
Journal Article
Closed access
PDF file
VHVincent Huberty
Vincent Huberty
Ivo BoskoskiIvo Boskoski
Ivo Boskoski
VBVincenzo Bove
Vincenzo Bove
POPauline Van Ouytsel
Pauline Van Ouytsel
GCGuido Costamagna
Guido Costamagna
JDJacques Devière
Jacques Devière
Objective: Endoscopic suture gastroplasty (ESG) has been developed as an alternative treatment for moderately obese patients. We present our results of a short-term randomised controlled trial on a new suturing technique, the Endomina system (E-ESG, Endo Tools therapeutics, Belgium).Design: Eligible patients (body mass index 30–40 kg/m2) were randomised in a 2:1 ratio to receive lifestyle modification plus E-ESG or lifestyle modification alone (control group); dietetic counselling and follow-up were identical. Endpoints included a mean excess weight loss (EWL) of more than 25% 12 months after E-ESG and a 15% EWL difference at 6 months between groups. At 6 months, a cross-over to E-ESG was offered to the control group. All patients were followed for a total of 12 months after E-ESG.Results: Of the 71 patients included (five male, mean age 40 years), mean EWL at 6 months was significantly higher in the treatment (38.6%, n=45) than in the control group (13.4%, n=21; p<0.001). At 6 months, satiety tests demonstrated a higher decrease in mean volume (41% vs 2.5%, p<0.001), and mean quality of life (QoL) was also higher in the treatment group (52.8 vs 45.1 p<0.05). No procedure-related or device-related severe adverse events were observed. Twelve months follow-up after E-ESG showed a mean EWL of 45.1%, which translated into a total body weight loss of 11.8%.Conclusions: This study demonstrates that E-ESG is safe and effective, providing a 25% better EWL at 6 months than lifestyle modification alone. This weight loss was maintained and resulted in a significant improvement in QoL up to 18 months after treatment.Trial registration number: NCT03255005.

15 June 2018 in Endoscopy
Verified
Journal Article
Closed access
PDF file
VHVincent Huberty
Vincent Huberty
EMEvzen Machytka
Evzen Machytka
Ivo BoskoskiIvo Boskoski
Ivo Boskoski
MBMarie Barea
Marie Barea
GCGuido Costamagna
Guido Costamagna
JDJacques Deviere
Jacques Deviere
Background Obesity is the pandemic disease of this century. Surgery is the only effective treatment but cannot be offered to every patient. Endoscopic sutured gastroplasty is a minimally invasive technique that may potentially fill the gap between surgery and behavioral therapy. In this study, we prospectively investigated the efficacy and safety of a novel suturing device. Methods After a pre-bariatric multidisciplinary work-up, class 1 and 2 obese patients were included. Using a simple triangulation platform, transmural sutures with serosa-to-serosa apposition were performed in the gastric cavity. Patients were followed according to the same routines as those performed for bariatric procedures. Results Between November 2015 and December 2016, 51 patients were included across three European Centers. Mean body mass index at baseline was 35.1 kg/m2 (SD 3.0). Excess weight loss and total body weight loss at 1 year were 29 % (SD 28) and 7.4 % (SD 7), respectively, for the whole cohort (45 patients). At follow-up gastroscopy, 88 % of sutures were still in place (30 patients). No severe adverse events were observed. Conclusions Endoscopic sutured gastroplasty using this novel device is safe and achieved weight loss results in line with criteria expected for these endoluminal techniques. Further prospective studies vs. placebo or nutritional support are needed.

1 February 2020 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
SLSundeep Lakhtakia
Sundeep Lakhtakia
NRNageshwar Reddy
Nageshwar Reddy
WDWerner Dolak
Werner Dolak
TPThierry Ponchon
Thierry Ponchon
MBMarco J. Bruno
Marco J. Bruno
DCDavid Carr-Locke
David Carr-Locke

1 April 2017 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
VHVincent Huberty
Vincent Huberty
MIMostafa Ibrahim
Mostafa Ibrahim
MHMartin Hiernaux
Martin Hiernaux
ACAlexandre Chau
Alexandre Chau
SDSonia Dugardeyn
Sonia Dugardeyn
JDJacques Devière
Jacques Devière

20 April 2018 in Digestive Diseases
Verified
Journal Article
Closed access
PDF file
AHAlia Hadefi
Alia Hadefi
VHVincent Huberty
Vincent Huberty
ALArnaud Lemmers
Arnaud Lemmers
MAMarianna Arvanitakis
Marianna Arvanitakis
DMDavid Maggs
David Maggs
JDJacques Devière
Jacques Devière
Type 2 diabetes is a pandemic disease with an incidence that has risen steadily over recent decades. Experimental evidence in animals has demonstrated that intestinal bypass surgery of the upper small intestine, particularly the duodenum, has an important role in glucose homoeostasis. Furthermore, Roux-en-Y bypass performed as bariatric surgery has shown to correct hyperglycaemia from the first postoperative days in obese diabetic patients. Therefore, on the basis of these considerations, duodenal mucosal resurfacing was studied in type 2 diabetes patients as a minimally invasive procedure that could offer an alternative treatment for these patients. Further studies, and particularly large controlled trials, are needed to determine the place of this procedure in the treatment of type 2 diabetes as well as other metabolic diseases such as non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.